Scalp Irradiation with 3D-Milled Bolus: Initial Dosimetric and Clinical Experience

Author:

Dibs Khaled1,Gogineni Emile1ORCID,Jhawar Sachin M.1ORCID,Baliga Sujith1,Grecula John C.1,Mitchell Darrion L.1ORCID,Palmer Joshua1ORCID,Haglund Karl1,Andraos Therese Youssef1,Zoller Wesley1,Ewing Ashlee1,Bonomi Marcelo2ORCID,Bhateja Priyanka2ORCID,Tinoco Gabriel2ORCID,Liebner David2,Rocco James W.3,Old Matthew3,Gamez Mauricio E.4,Chakravarti Arnab1,Konieczkowski David J.1,Blakaj Dukagjin M.1

Affiliation:

1. Department of Radiation Oncology, The Ohio State University Wexner Medical Center, 460 W. 10th Ave., Columbus, OH 43210, USA

2. Department of Medical Oncology, The Ohio State University Wexner Medical Center, 460 W. 10th Ave., Columbus, OH 43210, USA

3. Department of Otolaryngology, The Ohio State University Wexner Medical Center, 460 W. 10th Ave., Columbus, OH 43210, USA

4. Department of Radiation Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA

Abstract

Background and purpose: A bolus is required when treating scalp lesions with photon radiation therapy. Traditional bolus materials face several issues, including air gaps and setup difficulty due to irregular, convex scalp geometry. A 3D-milled bolus is custom-formed to match individual patient anatomy, allowing improved dose coverage and homogeneity. Here, we describe the creation process of a 3D-milled bolus and report the outcomes for patients with scalp malignancies treated with Volumetric Modulated Arc Therapy (VMAT) utilizing a 3D-milled bolus. Materials and methods: Twenty-two patients treated from 2016 to 2022 using a 3D-milled bolus and VMAT were included. Histologies included squamous cell carcinoma (n = 14, 64%) and angiosarcoma (n = 8, 36%). A total of 7 (32%) patients were treated in the intact and 15 (68%) in the postoperative setting. The median prescription dose was 66.0 Gy (range: 60.0–69.96). Results: The target included the entire scalp for 8 (36%) patients; in the remaining 14 (64%), the median ratio of planning target volume to scalp volume was 35% (range: 25–90%). The median dose homogeneity index was 1.07 (range: 1.03–1.15). Six (27%) patients experienced acute grade 3 dermatitis and one (5%) patient experienced late grade 3 skin ulceration. With a median follow-up of 21.4 months (range: 4.0–75.4), the 18-month rates of locoregional control and overall survival were 75% and 79%, respectively. Conclusions: To our knowledge, this is the first study to report the clinical outcomes for patients with scalp malignancies treated with the combination of VMAT and a 3D-milled bolus. This technique resulted in favorable clinical outcomes and an acceptable toxicity profile in comparison with historic controls and warrants further investigation in a larger prospective study.

Publisher

MDPI AG

Reference36 articles.

1. National Comprehensive Cancer Network (2023, June 19). Squamous Cell Skin Cancer (Version 01.2023). Available online: https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf.

2. Prognostic variables in high-risk cutaneous squamous cell carcinoma: A review;Cheng;J. Cutan. Pathol.,2016

3. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection;Rowe;J. Am. Acad. Dermatol.,1992

4. Surgical margins for excision of primary cutaneous squamous cell carcinoma;Brodland;J. Am. Acad. Dermatol.,1992

5. Survival of Patients with Cutaneous Squamous Cell Carcinoma: Results of a Prospective Cohort Study;Eigentler;J. Investig. Dermatol.,2017

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3